Related Experiment Video
Updated: May 29, 2026
11:02
Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development
Published on: October 30, 2013
Chemotherapy in advanced bladder cancer: current status and future
Nabil Ismaili1, Mounia Amzerin, Aude Flechon
1Medical Oncology, Centre régional d'oncologie, Agadir, Morocco. ismailinabil@yahoo.fr
Journal of Hematology & Oncology
|September 13, 2011
Summary
Chemotherapy, particularly cisplatin-based regimens, is a standard treatment for advanced bladder cancer in fit patients. For those unable to tolerate cisplatin, carboplatin-based options offer effective alternatives.
Area of Science:
- Urology
- Medical Oncology
- Cancer Research
Background:
- Bladder cancer is a significant cause of cancer morbidity and mortality in men.
- Transitional cell carcinoma is the predominant histological type.
- Bladder cancer demonstrates high sensitivity to chemotherapy.
Purpose of the Study:
- To review the role of chemotherapy in managing advanced transitional cell carcinoma of the bladder.
- To highlight current chemotherapy standards and emerging targeted therapies.
Main Methods:
- Literature review of studies on advanced bladder cancer treatment.
- Analysis of chemotherapy regimens including cisplatin and carboplatin.
- Evaluation of targeted therapies in combination with chemotherapy.
Main Results:
- Cisplatin-based chemotherapy (MVAC, GC) is standard for fit patients with good performance status and renal function (GFR > 60 mL/min).
- Carboplatin-based regimens (gemcitabine plus carboplatin, MCAVI) are suitable for patients unfit for cisplatin.
- Targeted therapies, especially those inhibiting angiogenesis, show promise.
Conclusions:
- Chemotherapy remains a cornerstone in the management of advanced bladder cancer.
- Treatment selection depends on patient performance status and renal function.
- Targeted therapies represent a promising area for future bladder cancer treatment strategies.
Related Concept Videos
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:49Cancer Therapies
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
02:56Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
02:56Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
02:50Combination Therapies and Personalized Medicine
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
01:27Tumor Immunotherapy
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.